Articles tagged with Clinical Trials
The NIH is conducting a clinical trial to investigate rare but serious systemic allergic reactions to COVID-19 mRNA vaccines. Participants will receive a second dose of vaccine under controlled conditions to determine safe dosing, while breathing tests and blood draws monitor their response. The study aims to provide insights into mech...
Fosfomycin, a long-dormant antibiotic, has been revived as a potential treatment for multidrug-resistant E. coli infections. The study involved 143 patients with invasive urinary tract infections and found effective results, offering an alternative to last-resort antibiotics.
A new study found that music and auditory beat stimulation can significantly reduce state anxiety in people with moderate trait anxiety. The treatment was more effective than music alone or pink noise for reducing somatic anxiety, while music alone was more effective for reducing cognitive state anxiety.
Researchers found that four-month treatment is as effective as six months in non-severe TB cases, allowing for savings on screening and training healthcare workers. The study's results led to a change in the World Health Organisation's global guidelines, recommending a shorter treatment course for children with non-severe TB.
A randomized clinical trial found that low-cost letters encouraging individuals to complete the enrollment process resulted in a significant increase in health insurance enrollment. The study suggests that such letters could be an effective tool for promoting health insurance coverage, particularly among underserved populations.
A new study published in JAMA Network Open finds that a combination treatment of nicotine replacement therapy and varenicline is more effective for smoking cessation in heavy drinkers, resulting in 44.3% abstinence rate. Participants also showed significant reductions in drinking rates, with 25% decrease in weekly drinking days.
Researchers found that a community-based approach to reporting APOL1 genetic test results resulted in lower blood pressure readings among hypertensive patients. This trial suggests that involving communities in genetic testing could be beneficial for reducing the risks of chronic kidney disease.
The Phase 1b/2a clinical trial found that AB-2004 lowered blood and urinary levels of gut-derived metabolites and improved irritability and anxiety in adolescents with Autism Spectrum Disorder. The study's results support the potential of AB-2004 as a novel therapeutic approach for treating co-occurring conditions associated with ASD.
A new study will measure the effectiveness of oral hygiene in preventing non-ventilator hospital-acquired pneumonia (NVHAP) among hospitalized patients. NVHAP is the most deadly and costly type of hospital-acquired infection, affecting approximately one in 100 hospitalized patients.
Melanoma referral centers worldwide have adopted systemic therapies to treat high-risk melanoma, reducing the need for lymph node removal surgeries. The shift in treatment plans was driven by rapid adoption of effective treatments and a desire to avoid lifelong complications of surgery.
The HEALEY ALS Platform Trial is a groundbreaking approach to drug testing and treatment development for amyotrophic lateral sclerosis (ALS). With over 800 patients enrolled, the trial has already shown promising results, including a favorable active-to-placebo ratio of three to one in favor of receiving an active drug.
Computer simulations reveal metformin's effectiveness in targeting diabetes and some cancers, but also its negative consequences for others. Researchers emphasize the need for precision medicine to individualize treatment based on patient profiles.
A new review highlights the need for greater gender diversity in clinical trial leadership, with women making up only 10.1% of committees. Increasing representation will help ensure medications are safe and effective for everyone, and pave the way for more women to present at scientific meetings.
A new phase II trial found that mid-treatment PET scans can help determine if patients with p16-positive oropharynx cancer can receive a lower dose of radiation therapy without compromising cancer control. The study reported fewer short-term side effects in patients who received de-escalated therapy.
Researchers from Tel Aviv University found that hyperbaric oxygen therapy (HBOT) relieves PTSD symptoms in treatment-resistant veterans, improving brain function and microstructure. The breakthrough study provides new hope for PTSD sufferers, offering an objective diagnostic tool and potential long-term improvements.
A 5-day course of oral ivermectin failed to reduce the risk of severe disease in high-risk patients with COVID-19. The study, published in JAMA Internal Medicine, suggests ivermectin may not be an effective treatment for COVID-19.
The COVID-19 pandemic has profoundly affected biomedical research, with a significant shift in priorities towards COVID-19-related studies. Publications and clinical trials in non-COVID fields decreased by up to 25%, while COVID-19-related research saw a surge in publications and grants.
Results from the Phase III EMPOWER trial demonstrate the efficacy of PD-1 inhibitor cemiplimab in improving overall survival for women with recurrent and/or metastatic cervical cancer. The study showed a 31% lower risk of death in patients receiving cemiplimab compared to chemotherapy.
Researchers will test the effectiveness of WeCAN, a group-based treatment designed to teach long-lasting management skills to individuals with traumatic brain injury and dementia. The study aims to identify behavioral, neuroimaging, and blood biomarkers that correlate with treatment efficacy.
The COXEN GC score was a significant predictor of overall survival when looking at both treatment groups combined. The study found no association between COXEN scores and progression-free survival, but the biomarker may serve as a potential tool to improve patient outcomes.
A small study found statistically significant improvements in various symptoms, including fatigue and chest discomfort, after EECP therapy in long COVID patients. Researchers believe this is the most plausible explanation for the benefits derived from EECP and its link to long COVID.
A new study on the Symbol Digit Modalities Test (SDMT) has found that group-level scores lack significance on an individual level. The normative study recommends a higher cut-off score for SDMT to accurately assess changes over time and predict disease progression.
The ALS Canada Research Program has awarded nine Discovery Grants to investigate critical areas of disease processes and clinical care. The grants will support fundamental laboratory research, biomarker studies, and clinical trials.
A clinical trial of niclosamide in COVID-19 patients found signals of benefit warranting further study. The medication showed potential in reducing contagiousness and symptoms, particularly in higher-risk populations.
Many pragmatic trials fail to collect patient-reported data on experience, burden of disease, and quality of life. Despite this, the authors suggest that including patient-reported outcomes can provide valuable insights into patient well-being. The study urges researchers to prioritize patient-centered approaches in clinical trials.
A new study found that increasing sleep duration by an average of 1.2 hours per night reduced participants' overall caloric intake by an average of 270 kcal per day. This translates to roughly 12 kg, or 26 lbs., of weight loss over three years if the effects were maintained.
Researchers from Tel Aviv University have engineered 3D human spinal cord tissues and implanted them in lab models with long-term chronic paralysis, resulting in an 80% success rate in restoring walking abilities. The team aims to conduct clinical trials in human patients within a few years to make the treatment commercially available.
A new 'bionic' pacemaker is being developed to restore the natural variability of the heartbeat, which has been found to improve cardiac output by 20%. This innovation could revolutionize the treatment of heart failure in New Zealand patients.
A phase 2 clinical trial found that the Australian-developed neonatal rotavirus vaccine RV3-BB was safe and produced a robust immune response in African babies. The reduced dose of the vaccine generated an equivalent immune response as the highest dose, offering opportunities to reduce vaccine manufacturing costs.
The NRG-GOG 0281/LOGS trial demonstrated that trametinib significantly reduces disease progression and improves response rates in women with recurrent low-grade serous carcinoma of the ovary/peritoneum. The study found a trend towards higher overall survival rates when compared to standard of care options.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
Women with GAD exhibit abnormal interoception, perceiving intense heartbeats and lower neural activity in the ventromedial prefrontal cortex. The study suggests a causal link between cardiovascular sensitivity and frontal cortex insensitivity, contributing to anxiety symptoms.
The ACC cardiooncology course is designed to educate clinicians on improving awareness, identification, monitoring, and management of cardiovascular diseases in cancer patients. The course aims to help clinicians minimize cardiotoxicity from cancer therapies, leading to improved overall survival and quality of life for oncology patients.
A clinical trial has found selinexor to be effective in shrinking tumors in almost a third of patients with recurrent glioblastoma, an aggressive brain cancer. The treatment induced responses in certain patients and allowed some to stay on the medication for over 12 months.
A randomized clinical trial examined how users interpret instructions and results from at-home tests, affecting quarantine decisions. The study found that many users misinterpret test results or do not follow recommended quarantine protocols.
A Dartmouth study reveals that consumers using at-home COVID-19 self tests may misinterpret the implications of their test results, leading to either unnecessary or inadequate quarantine. The study suggests that individuals at high risk for infection should still quarantine after a negative test result.
A clinical trial found that combining remdesivir with hyperimmune intravenous immunoglobulin did not improve health status or safety for adults hospitalized with COVID-19. The trial also showed a higher risk of adverse outcomes among patients who generated SARS-CoV-2-neutralizing antibodies before treatment.
A new care pathway has been shown to reduce long-term pain and improve quality of life for people after knee replacement surgery. The STAR care pathway is cost-effective and could potentially save the NHS up to £14 million per year.
A recent study found that adding a booster dose of any COVID-19 vaccine to fully vaccinated adults elicits an immune response and is safe. The trial, sponsored by the NIAID, used 458 adults who received a full regimen of any EUA or approved COVID-19 vaccine.
A new study published in the British Journal of Sports Medicine found that resuming non-contact physical activity 72 hours after a concussion is safe for children and youth. The study, which involved 456 participants, showed that early return to physical activity can reduce symptoms and delayed recovery.
A review of 392 clinical trials found increased representation of diverse groups in dermatology trials for common skin conditions. The study also highlighted persistent disparities in clinical trial participation among underrepresented populations.
A novel technique transplants patient fat into the sole to reduce plantar fasciitis symptoms, improving quality of life and sports activities. The study laid groundwork for a larger clinical trial with promising results.
The Epstein Family Foundation has donated $50 million to USC and UC San Diego to accelerate Alzheimer's research and discover effective therapies for the disease. The collaboration aims to compress study design, patient recruitment, and clinical trials to expedite the discovery of better treatments and a cure.
A Children's Hospital Colorado study explores a neuromuscular training intervention to reduce injury risk in athletes returning from sports-related concussions. The research found that athletes who completed the 8-week training program had a significantly lower risk of time-loss injuries compared to those who did not participate.
The NRG-RTOG 1010 clinical trial found that adding trastuzumab to chemoradiation and surgery did not improve disease-free survival for HER2-positive esophageal adenocarcinoma patients. Despite this, the study highlights future research opportunities to explore combining trastuzumab with other HER2-targeting agents.
Sophie Paczesny's research aims to validate biomarker panels that help doctors predict chronic GVHD risk and adjust immune suppression treatments accordingly. The study uses machine learning algorithms to analyze stored plasma and blood cell samples from over 1,300 BMT recipients.
The NIH is awarding $170 million to clinics and centers for a precision nutrition study that will develop algorithms to predict individual responses to food and dietary routines. The Nutrition for Precision Health study will recruit 10,000 participants from the All of Us Research Program.
A study published in Science Advances found that cannabidiol (CBD) inhibited SARS-CoV-2 infection in human cells and mice, suggesting its potential as a preventative or early treatment for COVID-19. CBD's effects were confined to high purity doses and specific situations.
A new review and meta-analysis found that drug companies are increasingly disclosing negative study findings for antidepressants. While progress has been made, full transparency remains an issue, with researchers emphasizing the need to report all trial results, both positive and negative, to inform patient treatment.
A recent clinical trial conducted by Prof. Alexandra Durr's team found that riluzole does not improve symptoms in patients with spinocerebellar ataxia type 2, but provided valuable biomarkers for future trials. The study involved 45 patients and revealed a good tolerance and absence of adverse effects.
A meta-analysis published in The Lancet Oncology reveals that men with intermediate- and high-risk prostate cancer experience improved overall survival with the addition of hormone therapy to radiotherapy. The study found prolonged adjuvant hormone therapy benefits men, while neoadjuvant hormone therapy did not.
CERC-002, a cytokine neutralizer, has been shown to improve survival rates by 83.9% among hospitalized COVID patients compared to 64.5% with placebo. The treatment targets the immune response early on, preventing disease progression.
Researchers at West Virginia University are investigating the link between chronic stress and Alzheimer's disease using animal models. They aim to understand how xanthine oxidase may sabotage brain blood vessels in Alzheimer's patients, and explore whether a medication can block this pathway to keep the brain healthy.
The Cardiovascular Research Foundation (CRF) will host THT 2022 from February 1-2, 2022. The conference features new and emerging treatments for heart failure, including transcatheter approaches and innovative monitoring strategies.
The Rare Disease COA Consortium aims to optimize COA selection during medical product development for rare diseases. The consortium will identify and describe potentially fit-for-purpose publicly available COAs, reducing the time and cost associated with developing new ones.
A clinical trial found that people with severe alcohol disorder stayed off alcohol for longer when treated with low doses of ketamine combined with psychological therapy. The therapy showed promise in preventing relapse and improving liver function, with participants having lower depression rates after three months.
The NRG Oncology GOG 0261 trial demonstrated that paclitaxel and carboplatin is a non-inferior alternative to paclitaxel and ifosfamide for treating women with uterine carcinosarcoma. This regimen offers improved progression-free survival and overall survival compared to the current standard of care.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
A new graft strategy has reduced chronic graft-versus-host disease in leukemia patients by depleting naïve T cells from donor blood. The approach has shown promising results, with only 7% of patients developing chronic GVHD compared to 30-60% with standard treatment.
A registry study found that people with inflammatory RMDs, such as rheumatoid arthritis and psoriatic arthritis, tolerate their COVID vaccine well, with short-lived reactions being the most common side effect. The majority of participants were able to continue on their normal medication with no changes.